Answers are grounded in this paper and cite their sources.
Despite curative therapy, biochemical recurrence (BCR) remains a frequent obstacle in prostate cancer management. Traditional models relying solely on clinical and pathological factors offer suboptimal predictive performance. This study aimed to construct and assess a novel nomogram that combines clinicopathological indicators with immune-related variables for BCR prediction. This retrospective analysis included prostate cancer patients undergoing radical prostatectomy from January 2023 to December 2024. Eligibility required confirmed histology, absence of neoadjuvant therapy, and complete clinical, pathological, and follow-up records. Patients with incomplete data were excluded, as detailed in the STROBE flow chart. Cases were randomly assigned to training and validation cohorts at a 7:3 ratio. A predictive nomogram was built using multivariable logistic regression with collinearity diagnostics and LASSO sensitivity analysis in the training set. Model performance was evaluated via receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA) in both cohorts. Internal validation was performed using bootstrap resampling, and the CAPRA score was calculated for benchmark comparison. A total of 300 patients were enrolled, with BCR rates of 25.71% (54/210) and 26.67% (24/90) in the training and validation sets, respectively. Multivariable analysis identified Gleason score, prostate-specific antigen (PSA), pathological stage, surgical margin status, CD8+ tumor-infiltrating lymphocytes (CD8+ TILs), programmed death-ligand 1 (PD-L1), interleukin-6 (IL-6), transforming growth factor-β (TGF-β), and M2-type tumor-associated macrophages (TAMs) as independent risk factors (all P < 0.05). The nomogram showed AUCs of 0.888 (95% CI 0.836–0.940) in the training set and 0.787 (95% CI 0.652–0.936) in the validation set. The combined model outperformed the CAPRA-S score (AUC 0.888 vs. 0.768, P = 0.021). Calibration and DCA indicated acceptable model fit and net benefit across threshold probabilities of 0.08–0.86. The integrated model incorporating clinicopathological and immune microenvironment parameters showed good discrimination for BCR, but its sensitivity was limited. External validation in larger independent cohorts is warranted before clinical application.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: